* Today’s busted-IPO deep dive is on uniQure. Its gene-based therapies have demonstrated life-changing results in patients with Hemophilia B.
* While years away from commercialization, it has several attractive traits including a major collaboration deal with Bristol-Myers Squibb.
* This promising Tier 4 developmental concern seems worthy of a small stake within a well-diversified biotech portfolio at current prices.
